Sue Ann
CHASKA, MN. MAY 5, 1999 -- LIFECORE BIOMEDICAL, INC. (Nasdaq:LCBM) announced today that the Food and Drug Administration has accepted the Company’s filing of a premarket approval (PMA) application for its ferric hyaluronate product, INTERGELTM Adhesion Prevention Solution. In addition, the FDA granted the Company’s request for expedited review status of INTERGELTM Solution. Allowance of expedited review status was based on the potential for an adhesion prevention solution to provide a specific public health benefit by reducing the incidence, extent, and severity of newly formed adhesions, which may present a risk of serious morbidity. The product PMA is currently being reviewed by the FDA’s General and Plastic Surgery Devices panel, which will establish a subsequent public review date. Lifecore’s ferric hyaluronate is marketed in Europe by the Gynecare Division of Ethicon, Inc., a Johnson & Johnson Company, under the trademark, INTERGELTM Adhesion Prevention Solution.